Download Mental Health Bulletin, July 2008

Lung Cancer
August 2013
This bulletin covers aspects of lung cancer and should be of interest to multidisciplinary teams
working in this area.
Sections can include:
 Combined Modality Therapies
 Drug Therapy
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Supportive Care & Symptom Management
 Surgery
 Tobacco & Smoking
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you
would like to request a print copy, please submit your request online at
www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is
not intended to be comprehensive. Professional judgment should be exercised when appraising
the material. The Library takes no responsibility for the wording, content and accuracy of the
information supplied, which has been extracted in good faith from reputable sources. NHSGGC is
not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, [email protected]
1
Lung Cancer, August 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
General
Evans, W.K., Ung, Y.C., Assouad, N., et al. (2013). Improving the quality of lung cancer
care in Ontario: the lung cancer disease pathway initiative. Journal of Thoracic
Oncology: Official Publication of the International Association for the Study of Lung Cancer
8,7:876-882.
Fakhrejahani, F., Hashemi Sadraei, N. and Mekhail, T. (2013). The Role of Consolidation
Treatment in Locally Advanced Unresectable NSCLC. Current oncology reports
15,4:424-432.
Gridelli, C., Rossi, A., Airoma, G., et al. (2013). Treatment of pulmonary neuroendocrine
tumours: state of the art and future developments. Cancer treatment reviews
39,5:466-472.
Remon, J., Lianes, P., Martinez, S., et al. (2013). Malignant mesothelioma: new insights
into a rare disease. Cancer treatment reviews 39,6:584-591.
Rossi, A., Martelli, O. and Di Maio, M. (2013). Treatment of patients with small-cell lung
cancer: from meta-analyses to clinical practice. Cancer treatment reviews 39,5:498506.
Shin, J. and Temel, J. (2013). Integrating palliative care: when and how?. Current
opinion in pulmonary medicine 19,4:344-349.
Weiss, J.M. and Stinchcombe, T.E. (2013). Second-Line Therapy for Advanced NSCLC.
Oncologist 18,8:947-953.
Combined Modality Therapies
Cai, H., Lin, Y., Li, W., et al. (2013). Maintenance treatment with different strategies in
advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Clinical Lung Cancer 14,4:333-341.
Garrido, P., Rosell, R., Arellano, A., et al. (2013). Randomized phase II trial of nonplatinum induction or consolidation chemotherapy plus concomitant
chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung
Cancer Group 0008 study. Lung Cancer 81,1:84-90.
Griffioen, G.H., Lagerwaard, F.J., Haasbeek, C.J., et al. (2013). Treatment of multiple
primary lung cancers using stereotactic radiotherapy, either with or without
surgery. Radiotherapy & Oncology 107,3:403-408.
Horita, N., Miyazawa, N., Morita, S., et al. (2013). Preoperative Chemotherapy Is
Effective for Stage III Resectable Non-Small-Cell Lung Cancer: Metaanalysis of 16
Trials. Clinical Lung Cancer 14,5:488-494.
Kepka, L., Bujko, K., Bujko, M., et al. (2013). Target volume for postoperative
radiotherapy in non-small cell lung cancer: Results from a prospective trial.
Radiotherapy & Oncology 108,1:61-65.
Koning, C.C., Wouterse, S.J., Daams, J.G., et al. (2013). Toxicity of concurrent
radiochemotherapy for locally advanced non-small-cell lung cancer: a systematic
review of the literature. Clinical Lung Cancer 14,5:481-487.
Lawrence, Y.R., Paulus, R., Langer, C., et al. (2013). The addition of amifostine to
carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell
2
Lung Cancer, August 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG)
randomized trial 9801. Lung Cancer 80,3:298-305.
Mauguen, A., Pignon, J.P., Burdett, S., et al. (2013). Surrogate endpoints for overall
survival in chemotherapy and radiotherapy trials in operable and locally advanced
lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet
Oncology 14,7:619-626.
Ramalingam, S.S., Kotsakis, A., Tarhini, A.A., et al. (2013). A multicenter phase II study
of cetuximab in combination with chest radiotherapy and consolidation
chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer
81,3:416-421.
Sugawara, S., Maemondo, M., Tachihara, M., et al. (2013). Randomized phase II trial of
uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent
thoracic radiotherapy for locally advanced unresectable stage III non-small-cell
lung cancer: NJLCG 0601. Lung Cancer 81,1:91-96.
Sun, J.M., Ahn, Y.C., Choi, E.K., et al. (2013). Phase III trial of concurrent thoracic
radiotherapy with either first- or third-cycle chemotherapy for limited-disease
small-cell lung cancer. Annals of Oncology 24,8:2088-2092.
Verstegen, N.E., Oosterhuis, J.W., Palma, D.A., et al. (2013). Stage I-II non-small-cell
lung cancer treated using either stereotactic ablative radiotherapy (SABR) or
lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a
propensity score-matched analysis. Annals of Oncology 24,6:1543-1548.
Westeel, V., Quoix, E., Puyraveau, M., et al. (2013). A randomised trial comparing
preoperative to perioperative chemotherapy in early-stage non-small-cell lung
cancer (IFCT 0002 trial). European journal of cancer 49,12:2654-2664.
Drug & Targeted Therapy
Bepler, G., Williams, C., Schell, M.J., et al. (2013). Randomized international phase III
trial of ERCC1 and RRM1 expression-based chemotherapy versus
gemcitabine/carboplatin in advanced non-small-cell lung cancer. Journal of Clinical
Oncology 31,19:2404-2412.
Brown, T., Pilkington, G., Bagust, A., et al. (2013). Clinical effectiveness and costeffectiveness of first-line chemotherapy for adult patients with locally advanced or
metastatic non-small cell lung cancer: a systematic review and economic
evaluation. Health technology assessment (Winchester, England) 17,31:1-278.
Bylicki, O., Ferlay, C., Chouaid, C., et al. (2013). Efficacy of pemetrexed as second-line
therapy in advanced NSCLC after either treatment-free interval or maintenance
therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. Journal of
Thoracic Oncology: Official Publication of the International Association for the Study of Lung
Cancer 8,7:906-914.
Chaft, J.E., Rusch, V., Ginsberg, M.S., et al. (2013). Phase II Trial of Neoadjuvant
Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with
Resectable Nonsquamous Non-Small-Cell Lung Cancers. Journal of Thoracic Oncology:
Official Publication of the International Association for the Study of Lung Cancer 8,8:10841090.
Chen, G., Feng, J., Zhou, C., et al. (2013). Quality of life (QoL) analyses from OPTIMAL
(CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib
versus chemotherapy in patients with advanced EGFR mutation-positive non-smallcell lung cancer (NSCLC). Annals of Oncology 24,6:1615-1622.
3
Lung Cancer, August 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Cui, J., Cai, X., Zhu, M., et al. (2013). The efficacy of bevacizumab compared with
other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30
randomized controlled clinical trials. PLoS ONE [Electronic Resource] 8,4:e62038.
de Castria, T.B., da Silva, E.M., Gois, A.F., et al. (2013). Cisplatin versus carboplatin in
combination with third-generation drugs for advanced non-small cell lung cancer.
Cochrane Database of Systematic Reviews 8,009256.
Garassino, M.C., Martelli, O., Broggini, M., et al. (2013). Erlotinib versus docetaxel as
second-line treatment of patients with advanced non-small-cell lung cancer and
wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncology
14,10:981-988.
Groen, H.J., Socinski, M.A., Grossi, F., et al. (2013). A randomized, double-blind, phase
II study of erlotinib with or without sunitinib for the second-line treatment of
metastatic non-small-cell lung cancer (NSCLC). Annals of Oncology 24,9:2382-2389.
Heigener, D.F., von Pawel, J., Eschbach, C., et al. (2013). Prospective, multicenter,
randomized, independent-group, open-label phase II study to investigate the
efficacy and safety of three regimens with two doses of sagopilone as second-line
therapy in patients with stage IIIB or IV non-small-cell lung cancer. Lung Cancer
80,3:319-325.
Karayama, M., Inui, N., Kuroishi, S., et al. (2013). Maintenance therapy with
pemetrexed versus docetaxel after induction therapy with carboplatin and
pemetrexed in chemotherapy-naive patients with advanced non-squamous nonsmall-cell lung cancer: a randomized, phase II study. Cancer Chemotherapy &
Pharmacology 72,2:445-452.
Keith, R.L. and Miller, Y.E. (2013). Lung cancer chemoprevention: current status and
future prospects. Nature Reviews Clinical Oncology 10,6:334-343.
Kim, H.S., Mitsudomi, T., Soo, R.A., et al. (2013). Personalized therapy on the horizon
for squamous cell carcinoma of the lung. Lung Cancer 80,3:249-255.
Lim, S., Cho, B.C., Jung, J.Y., et al. (2013). Phase II study of camtobell inj. (belotecan)
in combination with cisplatin in patients with previously untreated, extensive stage
small cell lung cancer. Lung Cancer 80,3:313-318.
Morabito, A., Gebbia, V., Di Maio, M., et al. (2013). Randomized phase III trial of
gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced nonsmall cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung
Cancer 81,1:77-83.
Niho, S., Kenmotsu, H., Sekine, I., et al. (2013). Combination chemotherapy with
irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a
multicenter phase II study. Journal of Thoracic Oncology: Official Publication of the
International Association for the Study of Lung Cancer 8,7:980-984.
Obasaju, C., Bowman, L., Wang, P., et al. (2013). Identifying the target NSCLC patient
for maintenance therapy: an analysis from a placebo-controlled, phase III trial of
maintenance pemetrexed (H3E-MC-JMEN). Annals of Oncology 24,6:1534-1542.
Petrelli, F., Coinu, A., Cabiddu, M., et al. (2013). Platinum rechallenge in patients with
advanced NSCLC: A pooled analysis. Lung Cancer 81,3:337-342.
Rossi, A., Pasquale, R., Esposito, C., et al. (2013). Should epidermal growth factor
receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of
selected advanced non-small cell lung cancer patients? Cancer treatment reviews
39,5:489-497.
4
Lung Cancer, August 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Shaw, A.T., Kim, D.W., Nakagawa, K., et al. (2013). Crizotinib versus chemotherapy in
advanced ALK-positive lung cancer. New England Journal of Medicine 368,25:2385-2394.
Shi, Y., Zhang, L., Liu, X., et al. (2013). Icotinib versus gefitinib in previously treated
advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase
3 non-inferiority trial. Lancet Oncology 14,10:953-961.
Urata, Y., Okamoto, I., Takeda, M., et al. (2013). Phase 2 study of S-1 and carboplatin
plus bevacizumab followed by maintenance S-1 and bevacizumab for
chemotherapy-naive patients with advanced nonsquamous non-small cell lung
cancer. Cancer 119,12:2275-2281.
Vansteenkiste, J., Zielinski, M., Linder, A., et al. (2013). Adjuvant MAGE-A3
immunotherapy in resected non-small-cell lung cancer: phase II randomized study
results. Journal of Clinical Oncology 31,19:2396-2403.
Wu, Y.L., Lee, J.S., Thongprasert, S., et al. (2013). Intercalated combination of
chemotherapy and erlotinib for patients with advanced stage non-small-cell lung
cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncology 14,8:777-786.
Zhu, J., Sharma, D.B., Chen, A.B., et al. (2013). Comparative effectiveness of three
platinum-doublet chemotherapy regimens in elderly patients with advanced nonsmall cell lung cancer. Cancer 119,11:2048-2060.
Zukin, M., Barrios, C.H., Rodrigues Pereira, J., et al. (2013). Randomized Phase III Trial
of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With
Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group
Performance Status of 2. Journal of Clinical Oncology 31,23:2849-2853.
Pathology, Staging, Polymorphisms & Biomarkers
Chen, Z., Xu, L., Ye, X., et al. (2013). Polymorphisms of microRNA sequences or
binding sites and lung cancer: a meta-analysis and systematic review. PLoS ONE
[Electronic Resource] 8,4:e61008.
Daigo, Y., Takano, A., Teramoto, K., et al. (2013). A systematic approach to the
development of novel therapeutics for lung cancer using genomic analyses. Clinical
Pharmacology & Therapeutics 94,2:218-223.
Field, J.K., Oudkerk, M., Pedersen, J.H., et al. (2013). Prospects for population screening
and diagnosis of lung cancer. Lancet 382,9893:732-741.
Gadgeel, S.M. (2013). New targets in non-small cell lung cancer. Current oncology
reports 15,4:411-423.
Hoang, T., Dahlberg, S.E., Schiller, J.H., et al. (2013). Does histology predict survival of
advanced non-small cell lung cancer patients treated with platin-based
chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study
E1594. Lung Cancer 81,1:47-52.
Lindeman, N.I., Cagle, P.T., Beasley, M.B., et al. (2013). Molecular testing guideline for
selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors:
guideline from the College of American Pathologists, International Association for
the Study of Lung Cancer, and Association for Molecular Pathology. Journal of
Molecular Diagnostics 15,4:415-453.
5
Lung Cancer, August 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Lindeman, N.I., Cagle, P.T., Beasley, M.B., et al. (2013). Molecular testing guideline for
selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors:
guideline from the College of American Pathologists, International Association for
the Study of Lung Cancer, and Association for Molecular Pathology. Journal of
Thoracic Oncology: Official Publication of the International Association for the Study of Lung
Cancer 8,7:823-859.
Lindeman, N.I., Cagle, P.T., Beasley, M.B., et al. (2013). Molecular testing guideline for
selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors:
guideline from the College of American Pathologists, International Association for
the Study of Lung Cancer, and Association for Molecular Pathology. Archives of
Pathology & Laboratory Medicine 137,6:828-860.
Mazieres, J., Peters, S., Lepage, B., et al. (2013). Lung cancer that harbors an HER2
mutation: epidemiologic characteristics and therapeutic perspectives. Journal of
Clinical Oncology 31,16:1997-2003.
Rossi, G., Pelosi, G., Barbareschi, M., et al. (2013). Subtyping non-small cell lung
cancer: relevant issues and operative recommendations for the best pathology
practice. International Journal of Surgical Pathology 21,4:326-336.
Shepherd, F.A., Domerg, C., Hainaut, P., et al. (2013). Pooled analysis of the prognostic
and predictive effects of KRAS mutation status and KRAS mutation subtype in
early-stage resected non-small-cell lung cancer in four trials of adjuvant
chemotherapy. Journal of Clinical Oncology 31,17:2173-2181.
Prognosis, Survival & Risk Factors
Ghimire, S., Kyung, E. and Kim, E. (2013). Reporting Trends of Outcome Measures in
Phase II and Phase III Trials Conducted in Advanced-Stage Non-small-cell Lung
Cancer. Lung 191,4:313-319.
Petrelli, F. and Barni, S. (2013). Non-cancer-related mortality after cisplatin-based
adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis
of 16 randomized trials. Medical Oncology 30,3:641.
Shimada, Y., Saji, H., Yoshida, K., et al. (2013). Prognostic factors and the significance
of treatment after recurrence in completely resected stage I non-small cell lung
cancer. Chest 143,6:1626-1634.
Varlotto, J., Fakiris, A., Flickinger, J., et al. (2013). Matched-pair and propensity score
comparisons of outcomes of patients with clinical stage I non-small cell lung cancer
treated with resection or stereotactic radiosurgery. Cancer 119,15:2683-2691.
Radiotherapy & Imaging
Balik, S., Weiss, E., Jan, N., et al. (2013). Evaluation of 4-dimensional computed
tomography to 4-dimensional cone-beam computed tomography deformable image
registration for lung cancer adaptive radiation therapy. International journal of
radiation oncology, biology, physics 86,2:372-379.
Chen, L., Zhang, J., Bao, J., et al. (2013). Meta-analysis of diffusion-weighted MRI in
the differential diagnosis of lung lesions. Journal of Magnetic Resonance Imaging
37,6:1351-1358.
6
Lung Cancer, August 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Enache, I., Noel, G., Jeung, M.Y., et al. (2013). Impact of 3D Conformal Radiotherapy
on Lung Function of Patients with Lung Cancer: A Prospective Study. Respiration
86,2:100-108.
Jain, P., Baker, A., Distefano, G., et al. (2013). Stereotactic ablative radiotherapy in the
UK: current status and developments. British Journal of Radiology 86,1029:20130331.
Kovalchik, S.A., Tammemagi, M., Berg, C.D., et al. (2013). Targeting of low-dose CT
screening according to the risk of lung-cancer death. New England Journal of Medicine
369,3:245-254.
Mori, S., Inaniwa, T., Furukawa, T., et al. (2013). Effects of a difference in respiratory
cycle between treatment planning and irradiation for phase-controlled rescanning
and carbon pencil beam scanning. British Journal of Radiology 86,1028:20130163.
Pan, H., Rose, B.S., Simpson, D.R., et al. (2013). Clinical practice patterns of lung
stereotactic body radiation therapy in the United States: a secondary analysis.
American Journal of Clinical Oncology 36,3:269-272.
Samuels, M.A., Kandula, S., Koru-Sengul, T., et al. (2013). Stereotactic body
radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and
older: retrospective results from a multicenter consortium. Clinical Lung Cancer
14,4:446-451.
Shirvani, S.M., Juloori, A., Allen, P.K., et al. (2013). Comparison of 2 common radiation
therapy techniques for definitive treatment of small cell lung cancer. International
journal of radiation oncology, biology, physics 87,1:139-147.
Videtic, G.M. (2013). The role of radiation therapy in small cell lung cancer. Current
oncology reports 15,4:405-410.
Supportive Care & Symptom Management
Andersen, A.H., Vinther, A., Poulsen, L.L., et al. (2013). A modified exercise protocol
may promote continuance of exercise after the intervention in lung cancer patients-a pragmatic uncontrolled trial. Supportive Care in Cancer 21,8:2247-2253.
Bol, N., Smets, E.M., Rutgers, M.M., et al. (2013). Do videos improve website
satisfaction and recall of online cancer-related information in older lung cancer
patients?. Patient Education & Counseling 92,3:404-412.
Carlson, L.E., Waller, A., Groff, S.L., et al. (2013). Screening for distress, the sixth vital
sign, in lung cancer patients: effects on pain, fatigue, and common problemssecondary outcomes of a randomized controlled trial. Psycho-oncology 22,8:18801888.
Ganguli, A., Wiegand, P., Gao, X., et al. (2013). The impact of second-line agents on
patients' health-related quality of life in the treatment for non-small cell lung
cancer: a systematic review. Quality of Life Research 22,5:1015-1026.
Iyer, S., Taylor-Stokes, G. and Roughley, A. (2013). Symptom burden and quality of life
in advanced non-small cell lung cancer patients in France and Germany. Lung Cancer
81,2:288-293.
Maguire, R., Kotronoulas, G., Papadopoulou, C., et al. (2013). Patient-reported outcome
measures for the identification of supportive care needs in people with lung cancer:
are we there yet?. Cancer nursing 36,4:E1-17.
7
Lung Cancer, August 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Maguire, R., Papadopoulou, C., Kotronoulas, G., et al. (2013). A systematic review of
supportive care needs of people living with lung cancer. European Journal of Oncology
Nursing 17,4:449-464.
Mazzone, P.J., Obuchowski, N., Fu, A.Z., et al. (2013). Quality of life and healthcare use
in a randomized controlled lung cancer screening study. Annals of the American
Thoracic Society 10,4:324-329.
Miura, S., Watanabe, S., Sato, K., et al. (2013). The efficacy of triplet antiemetic
therapy with 0.75mg of palonosetron for chemotherapy-induced nausea and
vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Supportive Care in Cancer 21,9:2575-2581.
Payne, C., Larkin, P.J., McIlfatrick, S., et al. (2013). Exercise and nutrition interventions
in advanced lung cancer: a systematic review. Current Oncology 20,4:e321-37.
Surgery
Iwata, H. (2013). Minimally invasive pulmonary surgery for lung cancer, up to date.
General Thoracic & Cardiovascular Surgery 61,8:449-454.
Jaklitsch, M.T., Gu, L., Demmy, T., et al. (2013). Prospective phase II trial of
preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for
IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. Journal of
Thoracic & Cardiovascular Surgery 146,1:9-16.
Lang-Lazdunski, L. (2013). Surgery for nonsmall cell lung cancer. European Respiratory
Review 22,129:382-404.
Okada, M. (2013). Radical sublobar resection for small-diameter lung cancers.
Thoracic Surgery Clinics 23,3:301-311.
Palade, E., Passlick, B., Osei-Agyemang, T., et al. (2013). Video-assisted vs open
mediastinal lymphadenectomy for Stage I non-small-cell lung cancer: results of a
prospective randomized trial. European Journal of Cardio-Thoracic Surgery 44,2:244-249.
Poghosyan, H., Sheldon, L.K., Leveille, S.G., et al. (2013). Health-related quality of life
after surgical treatment in patients with non-small cell lung cancer: a systematic
review. Lung Cancer 81,1:11-26.
Raptakis, T., Boura, P., Tsimpoukis, S., et al. (2013). Endoscopic and endobronchial
ultrasound-guided needle aspiration in the mediastinal staging of non-small cell
lung cancer. Anticancer Research 33,6:2369-2376.
Zhang, Z., Zhang, Y., Feng, H., et al. (2013). Is video-assisted thoracic surgery
lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A
systematic review and meta-analysis. European Journal of Cardio-Thoracic Surgery
44,3:407-414.
Tobacco and Smoking
Guerriero, C., Cairns, J., Roberts, I., et al. (2013). The cost-effectiveness of smoking
cessation support delivered by mobile phone text messaging: Txt2stop. European
Journal of Health Economics 14,5:789-797.
8
Lung Cancer, August 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Please note that the journal articles you are accessing are subject to the terms and conditions
imposed by the publisher, so there will be a limit on the number of articles an individual may
download or print from a single issue of a journal. You can consult your local NHSGGC library with
any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
Sources used for this bulletin: OVID databases
9
Lung Cancer, August 2013
Kirsty Coltart, Subject Librarian, NHSGGC Library Network